Choosing a tirzepatide supplier: what the evidence and regulators actually say

What the trial data tells us, and why it attracted a counterfeit market

SURMOUNT-1's results were striking enough that clinicians across the UK took notice immediately. An average loss of around 20–21% of body weight over 72 weeks at the highest dose, with a tolerability profile that allowed most participants to complete the trial, set a new benchmark. The follow-on SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, put tirzepatide head-to-head with semaglutide 2.4 mg over the same period and found tirzepatide produced greater average weight reduction. NICE reviewed this body of evidence before publishing TA1026 in December 2024, the full appraisal is worth reading if you want to understand the committee's reasoning.

Those results created demand fast. And where pharmaceutical demand outstrips easy NHS access, an unregulated market tends to follow. By October 2025 the MHRA had raided a site in Northampton producing counterfeit tirzepatide pens, the first illicit UK manufacturing operation for this medicine. Fake pens seized in earlier enforcement actions had been found to contain insulin rather than the labelled drug, with some users hospitalised as a result. The enforcement picture is the backdrop for every supplier decision a patient makes.

For a read on what makes one supplier legitimate and another a red flag, the guide to finding the best Mounjaro supplier in the UK covers the practical checklist in detail.

What a legitimate UK tirzepatide supplier looks like in practice

Tirzepatide reaches patients through Eli Lilly's authorised UK supply chain, distributed to GPhC-registered pharmacies. That chain is how the medicine inside your pen stays the same as the medicine tested in SURMOUNT-1. Outside it, you have no meaningful way to verify what you're injecting.

A supplier operating legally will, at minimum: hold a GPhC pharmacy registration you can verify yourself; require a clinical consultation before issuing a prescription; have that prescription written by a named, qualified prescriber (not generated by software); and dispense from stock sourced through licensed UK wholesalers. None of those steps can be skipped. A supplier offering tirzepatide without a prior clinical assessment is not a legitimate supplier, regardless of how professional its website looks.

Red flags worth knowing: prices dramatically below current market rates; no requirement for a prescription; social-media sellers; payment methods that bypass standard card processing. The MHRA's guidance on reporting suspect sellers via the Yellow Card scheme is the right place to escalate concerns. If you're comparing options, the overview of Mounjaro suppliers and the guide to finding suppliers near you both work through what to check.

Clinical eligibility and the prescriber's role in supply decisions

A prescriber deciding whether to supply tirzepatide is doing more than ticking a BMI box. The licensed thresholds (BMI 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, type 2 diabetes, dyslipidaemia or obstructive sleep apnoea) are the starting point, not the whole picture. Contraindications, current medicines, medical history and the patient's goals all feed into a clinical judgement. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance.

At nume, a GPhC-registered Independent Prescriber personally reviews every consultation the same day. Photo-ID verification, live weight confirmation on video and Summary Care Record checks are part of that process. The pen goes in the fridge door once it arrives, but what matters is that a real clinician has decided it should be there at all. You can read more about the clinical team behind those decisions on the clinical team page.

If you're already on treatment and considering moving between providers, the guide to switching your Mounjaro supplier explains what evidence a new prescriber will want to see and what the clinical review process involves. More general questions about the full weight-loss treatment landscape are covered on our treatment overview.

Cost context and what a transparent supplier price actually includes

Tirzepatide pricing shifted significantly from 1 September 2025 when Eli Lilly raised its UK list price, reported figures suggest the 15 mg pen's list price rose from around £122 to around £330 per four-week pen, with private market prices typically ranging from roughly £149 to £375 per month depending on the dose and the provider. Those numbers matter for context, but price is genuinely the wrong primary filter for a prescription medicine.

A legitimate all-in price covers the consultation, the prescription, the dispensing, the clinical review, and aftercare support. A low headline price that hides prescription fees, consultation charges or delivery costs may look attractive until you add everything up. The honest cost breakdown for Mounjaro in the UK works through what to compare, and our page on Mounjaro supplies covers what comes with each order. At nume, one price covers everything, no subscriptions, no auto-renewals, free next-working-day delivery through DPD in plain packaging.

If you're ready to understand whether tirzepatide is clinically suitable for you, speaking to our prescribers is the natural next step.